Why hardware startups underestimate the second regulatory milestone

Revisiting a familiar theme

Two years after we first wrote about this pattern, it remains one of the most persistent traps in medical device building. The second submission still surprises founders.

What is new in 2026

Cybersecurity, AI change-control plans, and expanded post-market surveillance obligations have all been added to the second submission burden. The gap between first and second clearance has grown, not shrunk.

The updated advice

Hire a full-time regulatory lead before first clearance. Build the PCCP into the first submission when applicable. Lock supplier quality agreements early.

The strategic upside

Companies that treat the second submission as a strategic accelerator — expanding indications, opening new geographies — end up with a stronger competitive position than those that scramble reactively.

The gap between clearances

First clearance typically covers a narrower indication than the company's long-term commercial plan requires, and the second submission, whether an expanded indication or a next-generation device, often demands clinical evidence the team never collected because early trial design optimized for speed to first clearance rather than for future expansion.

This creates a structural stall: commercial teams are ready to sell into a broader market before the regulatory pathway to serve that market legally exists.

What is different this cycle

Reviewers are increasingly asking for real-world performance data gathered after first clearance as part of the evidence package for a second submission, which means companies that neglected post-market data collection now face a longer runway to their next milestone than companies that built the infrastructure early. This is a meaningful change from a few years ago, when post-market data played a smaller role in expansion submissions.

Planning backward

The updated advice is to design the first clinical study with an eye toward what evidence the second submission will require, even if that means collecting a small amount of additional data that has no bearing on the initial clearance itself. The marginal cost of that extra data collection early is far lower than the cost of a dedicated study run later under commercial pressure.

Why this becomes an advantage

Companies that treat the second milestone as part of the original regulatory strategy, rather than a separate future project, tend to reach expanded indications faster than competitors and can use that speed as a genuine differentiator when courting hospital systems that care about total addressable use cases, not just the initial cleared claim.

The team composition problem

Many device startups build their regulatory function around a single milestone, hiring or contracting expertise specifically to clear the first submission and then letting that capacity lapse once clearance arrives. When the second milestone approaches, the institutional knowledge of what the reviewers actually asked for the first time has often walked out the door with a departing consultant.

Companies that retain regulatory continuity across both milestones, even at higher fixed cost, consistently move faster through the second submission because they are not relearning lessons the organization already paid to learn once.

A note on capital planning

Boards frequently model runway assuming commercial revenue ramps immediately after first clearance, without reserving capital for the second regulatory cycle that expanded commercial plans actually require. The startups that avoid a painful bridge round are the ones that budgeted for the second milestone as a known cost from the outset, not as a surprise that emerges once the sales team hits its ceiling.